WE CLAIM:

1. A method of treating prostate cancer in a mammal comprising local administration of a composition having a therapeutically effective concentration of collagenase.

2. The method of claim 1, further comprising administering a glycosidase, a protease, a nuclease, a lipase, an esterase, a streptokinase, or a combination thereof.

3. The method of claim 2, wherein the glycosidase comprises hyaluronidase, neuraminidase, lysozyme, amylase, or a combination thereof.

4. The method of claim 2, wherein the protease comprises elastase, trypsin, chymotrypsin, pronase, dispase, bromelin, clostripain, thermolysin, subtilisin, papain, chymopapain, fibrinolysin, serrathiopeptidase, pancreatin, cathepsin–G, plasminogen activator, PMN leukocyte serine protease, or a combination thereof.

5. The method of claim 2, wherein the nuclease comprises DNase I, Rnase, or a combination thereof.

6. The method of claim 2, wherein the lipase comprises phospholipase.

7. The method of claim 2, wherein the esterase comprises cholesterol esterase.

8. The method of claim 2, comprising administering hyaluronidase trypsin, chymotrypsin, pronase, elastase, DNase I, dispase, fibrinolysin, or a combination thereof.

9. The method of claim 8, comprising administering hyaluronidase.

10. The method of claim 9, wherein the composition comprises collagenase at a concentration of about 250 to 250,000 U/ml and hyaluronidase at a concentration of about 160 to 160,000 U/ml.

11. The method of claim 10, wherein composition comprises hyaluronidase at a concentration of about 1,600 to 16,000 U/ml.

12. The method of claim 1, wherein the composition further comprises an effective concentration of a nonionic surfactant.

13. The method of claim 12, wherein the nonionic surfactant comprises an ethylene oxide ester of a C10–C20 fatty acid, an ethylene oxide ester of a C8–C22 alkyl alcohol, or a combination thereof.

14. The method of claim 12, wherein the nonionic surfactant comprises Triton® X–100.

15. The method of claim 1, wherein the composition further comprises an effective concentration of an antibiotic.

16. The method of claim 15, wherein the antibiotic comprises gentamicin.

17. The method of claim 1, wherein the composition further comprises an effective concentration of calcium ion.

18. The method of claim 17, wherein the composition comprises $CaCl_2$.

19. The method of claim 1, wherein the composition further comprises a hyaluronidase, a Triton® X–100, a gentamicin, and a calcium ion.

20. The method of claim 1, wherein local administration comprises intraprostatic injection.

21. The method of claim 20, wherein the intraprostatic injection comprises intralesional injection.

22. The method of claim 20, wherein the intraprostatic injection comprises transurethral injection.

23. A method of treating prostate cancer in a living mammal comprising local administration of a composition comprising a therapeutically effective concentration of collagenase in combination with a glycosidase, a protease, a nuclease, a lipase, an esterase, a streptokinase, or combination thereof.

24. A method of treating prostate cancer in a living mammal comprising activating PSA *in vivo.*

25. The method of claim 24, wherein activating PSA *in vivo* comprises administering calcium ion.

26. The method of claim 25, further comprising locally administering a therapeutically effective concentration of collagenase.

27. The method of claim 26, further comprising administering a nonionic surfactant an antibiotic, or a combination thereof.

28. The method of claim 26, further comprising administering a glycosidase, a protease, a nuclease, a lipase, an esterase, a streptokinase, or a combination thereof.

29. The method of claim 26, wherein the glycosidase comprises hyaluronidase, neuraminidase, lysozyme, amylase, or a combination thereof.

30. The method of claim 28, wherein the protease comprises elastase, trypsin, chymotrypsin, pronase, dispase, bromelin, clostripain, thermolysin, subtilisin, papain, chymopapain, fibrinolysin, serrathiopeptidase, pancreatin, cathepsin–G, plasminogen activator, PMN leukocyte serine protease, or a combination thereof.

31. The method of claim 24, wherein local administration comprises direct intraprostatic injection.

32. The method of claim 24, further comprising eliciting a host immune response.